Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + arsenic trioxide + melphalan + autologous hematopoietic stem cell transplantation
- Development stage
- Unknown
- Lead developer
- University of Miami
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This therapeutic regimen is a conditioning protocol for patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (ASCT). Developed and studied by the University of Miami, the regimen combines the proteasome inhibitor bortezomib, the apoptosis-inducing agent arsenic trioxide (ATO), and the high-dose alkylating agent melphalan. The rationale behind this combination is to leverage the synergistic effects of bortezomib and arsenic trioxide in sensitizing myeloma cells to the cytotoxic effects of high-dose melphalan. Following this intensive conditioning, patients receive an infusion of their own (autologous) hematopoietic stem cells to rescue the bone marrow and restore hematopoiesis.
- Brand names
- VelcadeTrisenoxAlkeran
- Other names
- ATO + Bortezomib + Melphalan conditioningBAM conditioning regimen
02
Targets
26S proteasomeTXNRD2 (Thioredoxin reductase 2)DNA
Beyond the preview
Go deeper on bortezomib + arsenic trioxide + melphalan + autologous hematopoietic stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + arsenic trioxide + melphalan + autologous hematopoietic stem cell transplantation.